Cargando…
Proteasome inhibition represses ERα gene expression in ER+ cells- a new link between proteasome activity and estrogen signaling in breast cancer
Estrogen receptor-alpha (ERα) is a major therapeutic target of hormonal therapies in breast cancer and its expression in tumors is predictive of clinical response. Protein levels of ERα are tightly controlled by the 26S proteasome, yet how the clinical proteasome inhibitor, bortezomib, impacts ERα r...
Autores principales: | Powers, Ginny L., Ellison-Zelski, Stephanie J., Casa, Angelo J., Lee, Adrian V., Alarid, Elaine T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837136/ https://www.ncbi.nlm.nih.gov/pubmed/19946334 http://dx.doi.org/10.1038/onc.2009.434 |
Ejemplares similares
-
The Proteasome Inhibitor Bortezomib Induces an Inhibitory Chromatin Environment at a Distal Enhancer of the Estrogen Receptor-α Gene
por: Powers, Ginny L., et al.
Publicado: (2013) -
Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor
por: Ellison-Zelski, Stephanie J, et al.
Publicado: (2010) -
Homeostasis of the ER redox state subsequent to proteasome inhibition
por: Oku, Yuki, et al.
Publicado: (2021) -
Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
por: Andreani, Cristina, et al.
Publicado: (2017) -
Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERα in Cells Modeling Primary and Metastatic Breast Cancer
por: Busonero, Claudia, et al.
Publicado: (2020)